{"organizations": [], "uuid": "32f7e54522a851fa3cb636a8760ee3daa8f4803b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-arqule-and-basilea-enter-into-excl/brief-arqule-and-basilea-enter-into-exclusive-license-agreement-for-derazantinib-idUSFWN1RU0SE", "country": "US", "domain_rank": 408, "title": "BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-04-17T19:03:00.000+03:00", "replies_count": 0, "uuid": "32f7e54522a851fa3cb636a8760ee3daa8f4803b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-arqule-and-basilea-enter-into-excl/brief-arqule-and-basilea-enter-into-exclusive-license-agreement-for-derazantinib-idUSFWN1RU0SE", "ord_in_thread": 0, "title": "BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib", "locations": [], "entities": {"persons": [{"name": "basilea", "sentiment": "none"}], "locations": [{"name": "eu", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "china", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "arqule inc", "sentiment": "negative"}, {"name": "arqule", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17 (Reuters) - ArQule Inc:\n* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA\n* ARQULE INC - UNDER TERMS OF AGREEMENT, ARQULE WILL RECEIVE AN UPFRONT PAYMENT OF $10 MILLION\n* ARQULE INC - ARQULE ELIGIBLE TO RECEIVE UP TO $336 MILLION INCLUDING UPFRONT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS\n* ARQULE - UNDER CERTAIN CIRCUMSTANCES, CO MAY HAVE OPPORTUNITY TO PROMOTE DERAZANTINIB IN U.S. DIRECTLY\n* ARQULE - ALSO ENTITLED TO RECEIVE STAGGERED SINGLE-DIGIT TO DOUBLE-DIGIT ROYALTIES ON NET SALES UPON COMMERCIALIZATION\n* ARQULE - BASILEA WILL BE RESPONSIBLE FOR ALL COSTS AND EXPENSES OF DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION IN ITS TERRITORY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T19:03:00.000+03:00", "crawled": "2018-04-17T15:29:27.002+03:00", "highlightTitle": ""}